Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16574 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Aditya K Gupta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Minoxidil, Pericardial Effusion, Alopecia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Low‐dose oral minoxidil (LDOM) is used to treat hair loss, but the literature on its safety profile is relatively sparse.
Aims
Using the FDA Adverse Event Reporting System (FAERS) database, we determined signals for adverse events (AEs) with LDOM use.
Methods
Four sets of case/noncase study disproportionality analyses were conducted to determine reporting odds ratio (ROR) for 10 AEs including pericardial effusion (PE). The oral minoxidil dose ranges were: (i) ≤1.25 mg (i.e., 0–1.25 mg), (ii) ≤2.5 mg (i.e., 0–2.5 mg), (iii) ≤5 mg (i.e., 0–5 mg), and (iv) ≤10 mg (i.e., 0–10 mg).
Results
For ≤1.25 mg, we detected a signal for PE (ROR = 16.41, 95% CI: 2.29, 117.37, p < 0.05). For ≤2.5 mg, the analyses detected a signal for PE (ROR = 13.30, 95% CI: 5.96, 29.68, p < 0.05); the ROR in the absence of cardiac impairment was 5.34 (95% CI: 1.33, 21.37, p < 0.05); in the presence of cardiac impairment, the ROR was 49.42 (95% CI: 18.27, 133.66, p < 0.05). A signal for PE was also detected at ≤5 and ≤10 mg. For PE, there was a significant ( p < 0.05) association with a patient outcome of “life threatening” only at the ≤10 mg dose range.
Conclusions
Our study, the first FAERS‐based signal detection study for LDOM, found significant associations between LDOM use and several AEs. In the absence of causal evidence, these correlations warrant more attention regarding safe use of LDOM. Until more safety data are available, we recommend using LDOM at the lowest effective dose (≤5 mg/day).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
- Division of Cardiology, Women's College Hospital and University Health Network, Toronto, Ontario, Canada.
- Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Farjo Hair Institute, London, UK.
- Miller School of Medicine, University of Miami, Miami, Florida, USA.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder
Zitieren
APA
Gupta, A. K., Bamimore, M. A., Abdel-Qadir, H., Williams, G., Tosti, A., Piguet, V., & Talukder, M. (2025). Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16574
Vancouver
Gupta AK, Bamimore MA, Abdel-Qadir H, Williams G, Tosti A, Piguet V, et al. Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16574
BibTeX
@article{Gupta2025,
author = {Gupta, Aditya K and Bamimore, Mary A and Abdel-Qadir, Husam and Williams, Greg and Tosti, Antonella and Piguet, Vincent and Talukder, Mesbah},
title = {Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16574}
}
EUVIMED